The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

Publications

Vargas A, Montironi C, Buxó E

Organizing pneumonia with fatal outcome after adjuvant chemotherapy with FOLFOX.

Archivos de bronconeumologia. 2015;51(11):610

Kobayashi T, Masaki T, Kogawa K, Matsuoka H, Sugiyama M

Hemoptysis and acute respiratory syndrome (ARDS) as delayed-type hypersensitivity after FOLFOX4 plus bevacizumab treatment.

International surgery. 2013;98(4):445-9

Hannan LM, Yoong J, Chong G, McDonald CF

Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer.

Radiology and oncology. 2012;46(4):360-2

Prochilo T, Abeni C, Bertocchi P, Zaniboni A

Oxaliplatin-induced lung toxicity. Case report and review of the literature.

Current drug safety. 2012;7(2):179-82

Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, Gajic O

Drug-associated acute lung injury: a population-based cohort study.

Chest. 2012;142(4):845-850